Competitive Rivalry

BYSI competes in oncology drug development against larger global peers with broader pipelines and commercial infrastructure, limiting its pricing leverage and partner bargaining power.

Late-stage oncology markets are crowded with differentiated mechanisms, so peer competition for trial sites, investigators, and licensing attention compresses expected margins and deal terms.

Because BYSI remains development-stage, rivalry is expressed through capital-market and partnering competition rather than product pricing, leaving it structurally weaker than scaled peers.

Threat Of New Entrants

Regulatory, clinical, and manufacturing hurdles raise entry barriers in oncology, but they are not prohibitive because well-funded biotechs and platform companies still enter regularly.

BYSI faces similar scientific and approval barriers as global peers, so industry entry risk is meaningful but not uniquely punitive to its economics.

Patent protection and trial complexity slow entrants, yet they do not create durable insulation for BYSI versus better-capitalized competitors with broader asset portfolios.

Bargaining Power Of Suppliers

Specialized CROs, CDMOs, and clinical vendors can extract favorable terms from small biotechs, but BYSI faces the same supplier structure as most global development peers.

Supplier power is elevated by dependence on scarce oncology trial infrastructure, yet it mainly affects development spend rather than long-run product pricing power.

Compared with larger peers, BYSI has less volume leverage in outsourced R&D procurement, which can pressure margins and extend cash burn.

Bargaining Power Of Buyers

BYSI has limited direct buyer power because it is not yet a scaled commercial seller, so payers and hospitals do not materially constrain current pricing.

Future oncology buyers are highly concentrated and price-sensitive, but that pressure is similar across peers and becomes binding only after commercialization.

Relative to approved-drug peers, BYSI’s current buyer exposure is lower because its economics are driven more by financing and partnering than end-market pricing.

Threat Of Substitutes

In oncology, standard-of-care regimens and competing targeted therapies create strong substitution risk, which can cap eventual pricing and adoption versus peers with clearer differentiation.

Because many late-stage assets pursue overlapping indications, BYSI faces meaningful therapeutic substitution pressure if efficacy or safety advantages are not decisive.

Relative to peers with established labels or platform breadth, BYSI has less insulation from substitute mechanisms and combination regimens that can displace single-asset value.

Overall Score

BYSI’s industry structure is unfavorable versus global peers because rivalry and substitution are intense while buyer power remains latent but potentially severe after commercialization.